Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.5%

Tyra Biosciences, Inc. (NASDAQ:TYRA) shares traded up 6.5% during mid-day trading on Monday . The company traded as high as $16.78 and last traded at $16.69. 53,973 shares changed hands during trading, a decline of 58% from the average session volume of 129,241 shares. The stock had previously closed at $15.67.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Wedbush restated an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a research report on Thursday, March 21st. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target (up from $19.00) on shares of Tyra Biosciences in a report on Wednesday, March 20th.

Tyra Biosciences Price Performance

The firm has a market cap of $863.95 million, a PE ratio of -9.73 and a beta of 1.13. The business has a 50-day moving average price of $17.38 and a two-hundred day moving average price of $14.85.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Tuesday, March 19th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). Equities analysts expect that Tyra Biosciences, Inc. will post -1.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Daniel Bensen sold 9,587 shares of Tyra Biosciences stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $18.09, for a total transaction of $173,428.83. Following the completion of the sale, the chief operating officer now owns 452,981 shares in the company, valued at approximately $8,194,426.29. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last quarter, insiders sold 15,816 shares of company stock worth $298,165. 15.40% of the stock is owned by corporate insiders.

Institutional Trading of Tyra Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Simplex Trading LLC grew its holdings in Tyra Biosciences by 198.1% in the 3rd quarter. Simplex Trading LLC now owns 2,009 shares of the company’s stock valued at $27,000 after buying an additional 1,335 shares during the period. Federated Hermes Inc. grew its holdings in Tyra Biosciences by 1,244.2% in the 4th quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock valued at $29,000 after buying an additional 1,916 shares during the period. AJOVista LLC purchased a new stake in Tyra Biosciences in the 4th quarter valued at about $59,000. Exchange Traded Concepts LLC grew its holdings in Tyra Biosciences by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock valued at $132,000 after buying an additional 2,417 shares during the period. Finally, Corton Capital Inc. purchased a new stake in Tyra Biosciences in the 3rd quarter valued at about $152,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.